Abstract
Stimulating ovulation is a formidable procedure, and as such includes risk for complications commensurate with its intensity. One must always keep in mind the balance between expected benefits and predictable hazards. All aspects should be carefully explained to the couple who are, after all, the principal role players in this plan. Essentially all of the risk can be ascribed to excessive stimulation, of which there are two basic types: predictable problems, typically uncovered during a preliminary assessment of the couple’s fertility parameters that may be considered as primary prevention, and unpredictable problems, which appear during the treatment (i.e., secondary prevention).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adashi EY, Barri P, Berkovitz R et al (2003) Infertility therapy-associated multiple pregnancies (births): an ongoing epidemic. Reprod Biomed Online 7:515–542
Nouri K, Haslinger P, Szabo L et al (2014) Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS) – a retrospective case–control study. J Ovarian Res 7:54
D’Angelo A, Amso N (2002) “Coasting” (withholding gonadotropins) for prevention of ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 3:CD002811
Soares SR (2012) Etiology of OHSS and use of dopamine agonists. Fertil Steril 97:517–522
Pietrowski P, Szabo L, Sator M et al (2012) Ovarian hyperstimulation syndrome is correlated with a reduction of soluble receptor protein level and a higher amount of VEGF-A. Hum Reprod 27:196–199
Humaidan P, Quartarolo J, Papanikolaou EG (2010) Preventing ovarian hyperstimulayion syndrome: guidance for the clinician. Fertil Steril 94:389–400
Emperaire JC, Parneix I, Broussin B, Ruffie A (1988) Triggering ovulation with different doses of human chorionic gonadotropin (hCG) in stimulated cycles. In: 16th world congress on fertility and sterility, Abstract O-47, p 55
Abdalla HI, Ah-Moye M, Brindsen P (1987) The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on an in vitro fertilization program. Fertil Steril 48:958–963
Kolibianakis EM, Papanikolaou EG, Tournaye H et al (2007) Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovarian syndrome treated with gonadotropin-releasing hormone antagonist and recombinant follicle stimulating hormone. Fertil Steril 88:1382–1388
Chen D, Burmeister L, Goldschlag D, Rozenwaks Z (2003) Ovarian hyperstimulation syndrome: strategies for prevention. Reprod Biomed Online 7:43–49
Rosen MP, Meldrum DR (2012) Can FSH co-trigger prevent OHSS? Fertil Steril 97:534–535
The European Recombinant LH Study Group (2001) The recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multi-center double-blind study. J Clin Endocrinol Metab 86:2607–2618
Emperaire JC (1994) Le déclenchement thérapeutique de l’ovulation: vers le remplacement de l’HCG par l’LH. Contra Fertil Sexual 22:459–467
Kol S (2006) GnRH agonist trigger: looking for the coin under the lamppost? Hum Reprod 21:1328
Asch RH, Ivery G, Goldman M et al (1993) The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome. Hum Reprod 8:1015–1020
Nauck M, Karakiulakis G, Perruchaud AP et al (1998) Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309–315
Leitao VM, Moroni RM, Seko LM et al (2014) Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 101:664–675
Lainas TG, Kolibianakis LE, Sfontouris AI et al (2012) Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 10:69–74
Lainas GT, Kolibianakis ME, Sfontouris AI et al (2013) Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe OHSS. Hum Reprod 28(7):1929–1942
Lainas GT, Kolibianakis AM, Sfontouris IA et al (2014) Serum vascular endothelial growth factor levels following gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. Hum Reprod 28:1929–1942
Lamazou F, Legouez A, Letouzey V (2011) Le syndrome d’hyperstimulation ovarienne: physiopathologie, facteurs de risque, prevention et prise en charge. J Gynacol Obstet Reprod 40:593–611
Casals G, Fábregues F, Pavesi M et al (2013) Conservative medical treatment of ovarian hyperstimulation syndrome: a single center series and cost analysis. Acta Obstet Gynecol Scand 92:686–691
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Emperaire, JC. (2015). Avoiding Complications. In: Ovulation Stimulation with Gonadotropins. Springer, Cham. https://doi.org/10.1007/978-3-319-18654-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-18654-2_8
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18653-5
Online ISBN: 978-3-319-18654-2
eBook Packages: MedicineMedicine (R0)